降低腹膜透析患者的心血管代谢风险：透析液的作用
Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution.
作者信息
Holmes Clifford J
机构信息
Renal Division, Baxter Healthcare, McGaw Park, Illinois 60085, USA.
出版信息
J Diabetes Sci Technol. 2009 Nov 1;3(6):1472-80. doi: 10.1177/193229680900300629.
Abstract
Peritoneal dialysis (PD) is a well-established form of therapy for stage 5 chronic kidney disease requiring renal replacement therapy. D-Glucose has been used successfully for several decades as the osmotic agent employed in dialysis solutions to achieve adequate fluid removal. The absorption of 100-200 grams of glucose per day has been suggested as potentially increasing cardiometabolic risk, particularly in patients with diabetes. Supporting and undermining evidence for this hypothesis is reviewed, with a focus on the role of glucose absorption in changes in body composition, dyslipidemia, and glycemic control in diabetic PD patients. Clinical strategies to optimize fluid removal while minimizing the metabolic impact of glucose absorption are also discussed.
摘要
腹膜透析（PD）是终末期慢性肾病需要肾脏替代治疗时一种成熟的治疗方式。几十年来，D -葡萄糖已成功用作透析液中的渗透剂，以实现充分的液体清除。有人提出，每天吸收100 - 200克葡萄糖可能会增加心脏代谢风险，尤其是糖尿病患者。本文综述了支持和反驳这一假说的证据，重点关注葡萄糖吸收在糖尿病腹膜透析患者身体成分变化、血脂异常和血糖控制中的作用。还讨论了在优化液体清除的同时尽量减少葡萄糖吸收代谢影响的临床策略。
相似文献
1
Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution.
J Diabetes Sci Technol. 2009 Nov 1;3(6):1472-80. doi: 10.1177/193229680900300629.
2
Adverse effects of systemic glucose absorption with peritoneal dialysis: how good is the evidence?
Curr Opin Nephrol Hypertens. 2013 Nov;22(6):663-8. doi: 10.1097/MNH.0b013e328365b3d1.
3
Insulin resistance and glucose homeostasis in peritoneal dialysis.
Perit Dial Int. 2009 Feb;29 Suppl 2:S145-8.
4
Peritoneal dialysis in diabetic patients.
Contrib Nephrol. 2001(131):51-60. doi: 10.1159/000060060.
5
Biocompatible peritoneal dialysis solutions: do we have one?
Clin J Am Soc Nephrol. 2010 Apr;5(4):723-32. doi: 10.2215/CJN.05720809. Epub 2010 Jan 21.
6
Treatment targets for diabetic patients on peritoneal dialysis: any evidence?
Perit Dial Int. 2007 Jun;27 Suppl 2:S176-9.
7
Glucotoxicity in peritoneal dialysis--solutions for the solution!
Adv Chronic Kidney Dis. 2007 Jul;14(3):269-78. doi: 10.1053/j.ackd.2007.03.009.
8
[Peritoneal dialysis in patients with diabetic nephropathy].
Wien Klin Wochenschr. 2005;117 Suppl 6:29-34. doi: 10.1007/s00508-005-0483-z.
9
Peritoneal dialysis in patients with diabetes: are the benefits greater than the disadvantages?
Perit Dial Int. 2007 Jun;27 Suppl 2:S190-5.
10
Glucose absorption from peritoneal dialysate is associated with a gain in fat mass and a reduction in lean body mass in prevalent peritoneal dialysis patients.
Br J Nutr. 2020 Jun 14;123(11):1269-1276. doi: 10.1017/S0007114520000306. Epub 2020 Jan 29.
引用本文的文献
1
Comparison of clinical outcome between incremental peritoneal dialysis and conventional peritoneal dialysis: a propensity score matching study.
Ren Fail. 2021 Dec;43(1):1222-1228. doi: 10.1080/0886022X.2021.1960564.
2
Association between Dyslipidemia and Peritoneal Dialysis Technique Survival.
Open Access Maced J Med Sci. 2019 Jul 25;7(15):2467-2473. doi: 10.3889/oamjms.2019.664. eCollection 2019 Aug 15.
3
Regimen-related Mortality Risk in Patients Undergoing Peritoneal Dialysis Using Hypertonic Glucose Solution: A Retrospective Cohort Study.
J Prev Med Public Health. 2018 Jul;51(4):205-212. doi: 10.3961/jpmph.18.066. Epub 2018 Jun 19.
4
Hyperbranched polyglycerol is superior to glucose for long-term preservation of peritoneal membrane in a rat model of chronic peritoneal dialysis.
J Transl Med. 2016 Dec 13;14(1):338. doi: 10.1186/s12967-016-1098-z.
5
Fat tissue and inflammation in patients undergoing peritoneal dialysis.
Clin Kidney J. 2016 Jun;9(3):374-80. doi: 10.1093/ckj/sfw007. Epub 2016 Mar 24.
6
Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis.
Biomed Res Int. 2015;2015:208980. doi: 10.1155/2015/208980. Epub 2015 Dec 15.
7
Skin Autofluorescence and Mortality in Patients on Peritoneal Dialysis.
Medicine (Baltimore). 2015 Nov;94(45):e1933. doi: 10.1097/MD.0000000000001933.
8
Visceral fat area is associated with HbA1c but not dialysate-related glucose load in nondiabetic PD patients.
Sci Rep. 2015 Aug 4;5:12811. doi: 10.1038/srep12811.
9
Dynamic O-linked N-acetylglucosamine modification of proteins affects stress responses and survival of mesothelial cells exposed to peritoneal dialysis fluids.
J Am Soc Nephrol. 2014 Dec;25(12):2778-88. doi: 10.1681/ASN.2013101128. Epub 2014 May 22.
10
Low-Polydispersity Glucose Polymers as Osmotic Agents for Peritoneal Dialysis.
Perit Dial Int. 2015 Jul-Aug;35(4):428-35. doi: 10.3747/pdi.2013.00232. Epub 2014 Mar 1.
本文引用的文献
1
Tissue-advanced glycation end product concentration in dialysis patients.
Clin J Am Soc Nephrol. 2010 Jan;5(1):51-5. doi: 10.2215/CJN.05350709. Epub 2009 Nov 5.
2
Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients.
Perit Dial Int. 2009 Jul-Aug;29(4):422-32.
3
Relationship between dialysis modality and mortality.
J Am Soc Nephrol. 2009 Jan;20(1):155-63. doi: 10.1681/ASN.2007111188. Epub 2008 Dec 17.
4
Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
Am J Kidney Dis. 2009 Jan;53(1):138-50. doi: 10.1053/j.ajkd.2008.08.031. Epub 2008 Nov 25.
5
Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients.
J Ren Nutr. 2008 Nov;18(6):495-502. doi: 10.1053/j.jrn.2008.05.006.
6
Glycemic control in diabetic CKD patients: where do we stand?
Am J Kidney Dis. 2008 Oct;52(4):766-77. doi: 10.1053/j.ajkd.2008.04.011. Epub 2008 Jun 24.
7
Factors associated with body-fat changes in prevalent peritoneal dialysis patients.
J Ren Nutr. 2008 Jul;18(4):363-9. doi: 10.1053/j.jrn.2007.12.005.
8
Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis.
Ther Apher Dial. 2008 Jun;12(3):243-9. doi: 10.1111/j.1744-9987.2008.00581.x.
9
The leptin/adiponectin ratio: potential implications for peritoneal dialysis.
Kidney Int Suppl. 2008 Apr(108):S112-8. doi: 10.1038/sj.ki.5002611.
10
Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis.
Kidney Int. 2008 May;73(9):1062-8. doi: 10.1038/ki.2008.25. Epub 2008 Feb 20.
Zotero 插件